Commonwealth Equity Services LLC Has $842,000 Stock Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Commonwealth Equity Services LLC lifted its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) by 10.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 91,015 shares of the biotechnology company’s stock after purchasing an additional 8,640 shares during the quarter. Commonwealth Equity Services LLC owned about 0.12% of Anavex Life Sciences worth $842,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Teacher Retirement System of Texas lifted its stake in Anavex Life Sciences by 119.9% in the 3rd quarter. Teacher Retirement System of Texas now owns 25,383 shares of the biotechnology company’s stock valued at $262,000 after acquiring an additional 13,841 shares in the last quarter. Opus Capital Group LLC lifted its stake in Anavex Life Sciences by 60.6% in the 4th quarter. Opus Capital Group LLC now owns 26,500 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 10,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Anavex Life Sciences by 472.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 96,927 shares of the biotechnology company’s stock valued at $1,000,000 after acquiring an additional 80,005 shares in the last quarter. Bridgefront Capital LLC bought a new stake in Anavex Life Sciences in the 3rd quarter valued at approximately $105,000. Finally, Liberty One Investment Management LLC bought a new stake in Anavex Life Sciences in the 3rd quarter valued at approximately $138,000. 31.22% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Trading Down 2.5 %

AVXL opened at $9.26 on Wednesday. Anavex Life Sciences Corp. has a 1-year low of $7.36 and a 1-year high of $15.24. The stock’s fifty day simple moving average is $8.53 and its 200 day simple moving average is $9.64. The stock has a market cap of $748.58 million, a PE ratio of -13.62 and a beta of 0.75.

Anavex Life Sciences (NASDAQ:AVXL – Get Rating) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. Equities analysts forecast that Anavex Life Sciences Corp. will post -0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

AVXL has been the topic of several research reports. HC Wainwright boosted their target price on Anavex Life Sciences from $50.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 31st. BTIG Research dropped their price objective on Anavex Life Sciences from $35.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, February 9th. Finally, StockNews.com initiated coverage on Anavex Life Sciences in a research note on Thursday, May 18th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Anavex Life Sciences has a consensus rating of “Hold” and a consensus target price of $42.60.

Anavex Life Sciences Profile

(Get Rating)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome.